Early Renal Vasodilator and Hypotensive Action of Epoxyeicosatrienoic Acid Analog (EET-A) and 20-HETE Receptor Blocker (AAA) in Spontaneously Hypertensive Rats
Open Access
- 28 January 2021
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Physiology
Abstract
Cytochrome P450 (CYP-450) metabolites of arachidonic acid: epoxyeicosatrienoic acids (EETs) and 20-hydroxyeicosatetraenoic acid (20-HETE) have established role in regulation of blood pressure (BP) and kidney function. EETs deficiency and increased renal formation of 20-HETE contribute to hypertension in spontaneously hypertensive rats (SHR). We explored the effects of 14,15-EET analog (EET-A) and of 20-HETE receptor blocker (AAA) on BP and kidney function in this model. In anesthetized SHR the responses were determined of mean arterial blood pressure (MABP), total renal (RBF), and cortical (CBF) and inner-medullary blood flows, glomerular filtration rate and renal excretion, to EET-A, 5 mg/kg, infused i.v. for 1 h to rats untreated or after blockade of endogenous EETs degradation with an inhibitor (c-AUCB) of soluble epoxide hydrolase. Also examined were the responses to AAA (10 mg/kg/h), given alone or together with EET-A. EET-A significantly increased RBF and CBF (+30% and 26%, respectively), seen already within first 30 min of infusion. The greatest increases in RBF and CBF (by about 40%) were seen after AAA, similar when given alone or combined with EET-A. MABP decreased after EET-A or AAA but not significantly after the combination thereof. In all groups, RBF, and CBF increases preceded the decrease in MABP. We found that in SHR both EET-A and AAA induced renal vasodilation but, unexpectedly, no additive effect was seen. We suggest that both agents have a definite therapeutic potential and deserve further experimental and clinical testing aimed at introduction of novel antihypertensive therapy.Funding Information
- Narodowym Centrum Nauki
- Welch Foundation
- Dr. Ralph and Marian Falk Medical Research Trust
This publication has 37 references indexed in Scilit:
- Inhibition of soluble epoxide hydrolase by cis-4-[4-(3-adamantan-1-ylureido)cyclohexyl-oxy]benzoic acid exhibits antihypertensive and cardioprotective actions in transgenic rats with angiotensin II-dependent hypertensionClinical Science, 2012
- Epoxides and Soluble Epoxide Hydrolase in Cardiovascular PhysiologyPhysiological Reviews, 2012
- Inhibition of soluble epoxide hydrolase improves the impaired pressure–natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic ratsJournal of Hypertension, 2011
- Increases in plasmatrans-EETs and blood pressure reduction in spontaneously hypertensive ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2011
- Soluble epoxide hydrolase in the generation and maintenance of high blood pressure in spontaneously hypertensive ratsAmerican Journal of Physiology-Endocrinology and Metabolism, 2011
- Development of Epoxyeicosatrienoic Acid Analogs with in Vivo Anti-Hypertensive ActionsFrontiers in Physiology, 2010
- Orally Bioavailable Potent Soluble Epoxide Hydrolase InhibitorsJournal of Medicinal Chemistry, 2007
- Nitric oxide, superoxide and renal blood flow autoregulation in SHR after perinatal L‐arginine and antioxidantsActa Physiologica, 2007
- Differential Effects of 20-Hydroxyeicosatetraenoic Acid on Intrarenal Blood Flow in the RatThe Journal of pharmacology and experimental therapeutics, 2005
- 5,6-Epoxyeicosatrienoic Acid Mediates the Enhanced Renal Vasodilation to Arachidonic Acid in the SHRHypertension, 2003